First-Line Treatment for Opioid Use Disorder

Medication Options

• The American Academy of Pediatrics recommends buprenorphine as a first-line treatment for opioid use disorder in patients 16 years and older, due to its accessibility and favorable safety profile 2, 3
• Methadone is considered the gold standard of care for adults with opioid use disorder, but its use is limited by federal regulations requiring administration through certified Opioid Treatment Programs (OTPs) 2, 5
• Naltrexone may be considered for highly motivated patients who cannot or do not wish to take continuous opioid agonist therapy, but requires a minimum 7-10 day opioid-free period before initiation 1, 6

Essential Treatment Components

• The Centers for Disease Control and Prevention (CDC) recommends combining medication-assisted treatment with behavioral therapies and substance use disorder counseling to reduce opioid misuse and improve treatment retention 1, 4, 7
• The American College of Obstetricians and Gynecologists recommends offering buprenorphine or methadone to pregnant women with opioid use disorder to improve maternal outcomes 1, 4

Critical Implementation Points

• The Substance Abuse and Mental Health Services Administration (SAMHSA) recommends verifying opioid-free status before naltrexone initiation and ensuring patients are in mild-moderate withdrawal before first dose of buprenorphine to prevent precipitated withdrawal 4, 6
• The National Institute on Drug Abuse (NIDA) recommends providing naloxone for overdose prevention to all patients with opioid use disorder and monitoring liver function tests at baseline and every 3-6 months for naltrexone due to hepatotoxicity risk 1, 6

Common Pitfalls to Avoid

• The American Medical Association (AMA) recommends against initiating naltrexone without ensuring adequate opioid-free period and against withholding medication-assisted treatment due to stigma or misconceptions 2, 5, 6
• The World Health Organization (WHO) recommends against abrupt discontinuation of any medication-assisted treatment without tapering plan and close monitoring, and against prescribing naltrexone to patients requiring opioids for pain control as it blocks analgesic effects 6